Active, not recruitingPHASE2, PHASE3NCT03199469
A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)
Studying X-linked centronuclear myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Astellas Gene Therapies
- Principal Investigator
- Medical DirectorAstellas Pharma Global Development, Inc.
- Intervention
- Resamirigene bilparvovec(genetic)
- Enrollment
- 27 enrolled
- Eligibility
- 5 years · MALE
- Timeline
- 2017 – 2030
Study locations (6)
- UCLA Medical Center, Los Angeles, California, United States
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- National Institute of Neurological Disorders and Stroke/NIH Porter, Bethesda, Maryland, United States
- Hospital for Sick Children, Toronto, Ontario, Canada
- Hopital Armad Trousseau, Paris, France
- Kinderklinik und Kinderpoliklinik im Dr. Von Haunerschen Kinderspital Klinikum der Universitat Munchen, München, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03199469 on ClinicalTrials.govOther trials for X-linked centronuclear myopathy
Additional recruiting or active studies for the same condition.